leukemia
- Label
- leukemia (literal)
- Membro di
- Keywords of "Human terminal deoxynucleotidyl transferases as novel targets for anticancer chemotherapy." (Insieme di parole chiave)
- Parole chiave di "The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients." (Insieme di parole chiave)
- Parole chiave di "Diketo hexenoic acid derivatives are novel selective non-nucleoside inhibitors of mammalian terminal deoxynucleotidyl transferases, with potent cytotoxic effect against leukemic cells." (Insieme di parole chiave)
- Keywords of "Quinoline-Based p300 Histone Acetyltransferase Inhibitors with Pro-apoptotic Activity in Human Leukemia U937 Cells" (Insieme di parole chiave)
- Keywords of "Diketo hexenoic acid (DKHA) derivatives: the first class of selective non-nucleoside inhibitors of mammalian terminal deoxynucleotidyl transferases endowed with cytotoxic effect against leukemic cells." (Insieme di parole chiave)
- Keywords of "The bromodomain: a chromatin browser?" (Insieme di parole chiave)
- Value
- leukemia (literal)
Incoming links:
- Ha membro
- Parole chiave di "Diketo hexenoic acid derivatives are novel selective non-nucleoside inhibitors of mammalian terminal deoxynucleotidyl transferases, with potent cytotoxic effect against leukemic cells." (Insieme di parole chiave)
- Keywords of "Human terminal deoxynucleotidyl transferases as novel targets for anticancer chemotherapy." (Insieme di parole chiave)
- Keywords of "Quinoline-Based p300 Histone Acetyltransferase Inhibitors with Pro-apoptotic Activity in Human Leukemia U937 Cells" (Insieme di parole chiave)
- Keywords of "The bromodomain: a chromatin browser?" (Insieme di parole chiave)
- Keywords of "Diketo hexenoic acid (DKHA) derivatives: the first class of selective non-nucleoside inhibitors of mammalian terminal deoxynucleotidyl transferases endowed with cytotoxic effect against leukemic cells." (Insieme di parole chiave)
- Parole chiave di "The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients." (Insieme di parole chiave)
